|
Catalogue
Number
|
Product
|
Order number / Unit
|
|
|
9715
|
DOTA-[Pro1,Tyr4]bombesin (1-14)
|
9715.0001: 1 mg per vial
9715.0010: 10 mg per vial
Please inquire for customized
filling and bulk quantities.
|
|
|
Precursor for radiolabelled DOTA-[Pro1,Tyr4]bombesin (1-14)
|
|
|
|
|
|
|
|
|
Molar Mass: 2042.28
|
|
|
C90H136N28O25S
|
|
|
[593287-40-2] (net peptide)
|
|
|
|
|
|
Colourless to off-white freeze-dried solid packaged in dark glass screw cap vials.
|
|
|
|
|
|
|
|
|
Purity: ≥ 95 %
|
|
|
Certificates:
CoA; MS (identity) and HPLC (purity)
|
|
|
Chemical Name:
CA index name: Bombesin, 1-[1-[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-proline]-4-L-tyrosine-
|
|
|
Synonymes:
Bombesin, 1-[1-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-proline]-4-L-tyrosine-; MP2346; DOTA-[P1, Y4]BBN(1-14)
|
|
|
Literature:
1. Biddlecombe G.B. et al. Molecular imaging of gastrin-releasing peptide receptor-positive tumors in mice using 64Cu- and 86Y-DOTA-[Pro1,Tyr4]-bombesin(1-14). Bioconjug Chem. 2007, 18, 724-30.
|
|
|
2. Breeman W.A. et al. Evaluation of radiolabelled bombesin analogues for receptor-targeted scintigraphy and radiotherapy. Int J Cancer. 1999, 81, 658-65.
|
|
|
3. Breeman W.A. et al. Preclinical comparison of 111In-labeled DTPA- or DOTA-bombesin analogs for receptor targeted scintigraphy and radionuclide therapy. J. Nucl. Med. 2002, 43, 1650-56.
|
|
|
|
|
|
|
|
|
date of product catalogue issue:
05 April 2012
|